Pegylation: A novel process for modifying pharmacokinetics

Clinical Pharmacokinetics

Volumn 40, Issue 7, 2001, Pages 539-551

  Milton Harris, J ^a   Martin, Nancy E ^b   Modi, Marlene ^b  

^a Shearwater Corporation   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARAGINASE MACROGOL; CYTOKINE; GROWTH FACTOR; LIPOSOME; MACROGOL; PEGADEMASE; SCAVENGER;

ACUTE LEUKEMIA; ANTIGEN RECOGNITION; COMBINED IMMUNODEFICIENCY; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; IMMUNOGENICITY; KIDNEY CLEARANCE; PRIORITY JOURNAL; REVIEW; STEREOSPECIFICITY;

EID: 17844380498     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140070-00005     Document Type: Review

References (5)

1. Florence AT, Jani PU. Novel oral drug formulations: their potential in modulating adverse effects. Drug Saf 1994; 10: 233-66
2. Wills RJ, Ferraiolo BL. The role of pharmacokinetics in the development of biotechnologically derived agents. Clin Pharmacokinet 1992; 23: 406-14
3. Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 1991; 6: 133-51
4. Burnham NL. Polymers for delivering peptides and proteins. Am J Hosp Pharm 1994; 51: 210-8
5. Allen TM. Liposomes: opportunities in drug development. Drugs 1997; 54 Suppl. 4: 8-14